ArticleGHM open2024
The role of endocrine gland derived vascular growth factor/ Prokineticin-1 in human prostate cells.
Article in GHM open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In steroidogenic tissues, a novel class of angiogenic molecules known as endocrine gland-derived vascular endothelial growth factors (EG-VEGF)/prokineticins are primarily produced. Here, we investigated how EG-VEGF/ PROK1, a member of PROKs family, and its receptor are able to affect cellular motility in both non-neoplastic and cancerous human prostate cells. Using Western blot and motility test studies, EPN cells, a non-transformed cell line and Cancer Epithelial Prostatic Cells (CEPC) were employed as cellular models in the current investigation. Western blot examination of EPN normal prostate cells treated with EG-VEGF/PROK1 revealed that ERK1/2 was rapidly phosphorylated within 5, 10, and 20 minutes, while CEPC had high and sustained ERK1/2 activity at the same periods. Then, compared to normal EPN prostate cells, CEPC treated with EG-VEGF/PROK1 for up to 72 hours demonstrated enhanced cell motility. Based on our findings, EG-VEGF/PROK1 may play a role in prostate cancer progression by controlling angiogenesis and the motility of metastatic cells in CEPC cells, likely as a consequence of ERK1/2 activation, as contrasted to EPN normal prostate cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.